The Kansas City Chiefs have been a privileged bunch. They are one of the rare teams that hasn't been forced to worry about their quarterback situation. Between winning Super Bowls and division titles, ...

It was a win-and-in sort of Sunday for the Patriots, who sealed a playoff spot with a victory in Baltimore. Drake Maye led a long touchdown drive with just over two minutes to go that gave the ...

The video shows an extreme close-up view of the Airbus A380, revealing fine details around the cockpit and fuselage. It highlights design elements that are rarely seen from this distance on the ...

Donald Fred Amt, 78, of Indianapolis, passed away on Sunday, December 7, 2025. He was an architect. Survivors include his wife, Becky Amt; daughters, Lisa Cummins and Becky Messina-Graham; brother, ...

Japanese game makers are struggling to locate affordable commercial fonts after one of the country's leading font licensing services raised the cost of its annual plan from around $380 to $20,500 (USD ...

JetBlue Airways has expanded its internal aviation maintenance career pathway program to offer opportunities for external candidates to start their careers at the airline. The airline first launched a ...

Dropbox Backup is a nice perquisite for one-person account users, despite surcharges for long-term version retention. But the Backup feature for teams is entirely too cavalier with your data, moving ...

American Tower offers a compelling opportunity for dividend investors, with its stock down 20% from its 2025 peak and robust fundamentals. AMT benefits from defensive, consumer-independent revenue ...

Stocks ended higher on Monday on hopes of a potential end to what has become the longest U.S. government shutdown in history. Nov. 10, 2025 at 5:02 PM EST ...

Breakthroughs, discoveries, and DIY tips sent six days a week. Terms of Service and Privacy Policy. We’re taking more photos than ever, thanks to the convenience of ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game changer. The FDA no longer agrees that data ...